NCT07347379
Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
Enrolling by Invitation
Not specifiedAll AgesObservationalRxSight, Inc.
~500 participants
Updated 2026-01-16 on ClinicalTrials.gov
What's tested:Light Adjustable lens (LAL) and Light Delivery Device (LDD)Control IOL
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit compared between the RxSight LAL and Control group
Measured over Up to 55 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesTexas1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subject and study eye with prior participation in the CSP-029 study.
Exclusion
Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.
What this trial measures
- Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit compared between the RxSight LAL and Control groupUp to 55 months
- Mean manifest cylinder at the Long-Term follow up visit compared between the RxSight LAL and Control groupUp to 55 months